Date:February 13, 2013

Lisa Bomgaars, MD

Lisa Bomgaars, M.D.Director, Clinical Research Operations
Texas Children’s Cancer Center

Associate Professor
Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine

Dr. Lisa Bomgaars
1102 Bates Street, Suite 1590.01
Houston, TX 77030

Phone: 832-824-4268
Fax: 832-825-1453
Email: lbomgaars@txch.org

About Dr. Lisa Bomgaars

Dr. Lisa Bomgaars is a member of the Developmental Therapeutics Program and the Thrombosis Clinic. Her research focus relates to the pharmacologic study of new agents. She has experience with pre-clinical and clinical pharmacology research of novel oncologic agents and is a co-investigator on several studies evaluating novel anticoagulation agents for the treatment of thrombosis in pediatrics. Dr. Lisa Bomgaars is the Director of Clinical Research Operations for the Texas Children’s Cancer Center, and is also the Medical Director of the Research Resources Office (RRO) and Clinical Research Center at Baylor.

Education

M.D., Ohio State University College of Medicine
M.S., Graduate School of Biomedical Sciences at Baylor College of Medicine
Residency and Fellowship, Baylor College of Medicine
Clinical Scientist Training Program, Baylor College of Medicine

Board Certifications

American Board of Pediatrics
American Board of Pediatrics-Hematology/Oncology
American Board of Clinical Pharmacology

Selected Memberships

Medical Director, QA & Regulatory Affairs, Children’s Oncology Group (COG)
Member, Harris County Medical Society (HCMS) / Texas Medical Association (TMA)
Member, American Society of Clinical Oncologists (ASCO)
Member, American Society of Hematology (ASH)
Member, American Association for Cancer Research (AACR)
Member, American Society for Clinical Pharmacology and Therapeutics (ASCPT)
Member, International Society of Thrombosis and Haemostasis (ISTH)

Clinical Interests

Pediatric Pharmacology
New Drug Development
Pediatric Leukemia
Pediatric Lymphoma
Pediatric Hemostasis and Thrombosis

Research Interests

New drug development
Novel anticoagulation agents for the treatment of thrombosis
Pharmacogenetically guided warfarin therapy